Home : November 2019 : November 06, 2019 News : Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

November 06, 2019

CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a...

https://www.prnewswire.com:443/news-releases/artios-pharma-md-anderson-and-shangpharma-announce-in-licensing-agreement-for-dna-damage-response-inhibitor-300952071.html
Other Stories